A Double-Blind, Randomized, Vehicle-Control, Multicenter Study to Evaluate the Efficacy and Safety of NAFT900 in Children With Tinea Capitis Aged 6 to < 13 Years
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Naftifine (Primary)
- Indications Tinea capitis
- Focus Therapeutic Use
- Sponsors Merz North America; Merz Pharmaceuticals
- 08 Sep 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 21 Jul 2016 Planned End Date changed from 1 Sep 2016 to 1 Mar 2017.
- 21 Jul 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Dec 2016.